Northpond Ventures III GP, LLC bought $9.9M of KYTX
other at Kyverna Therapeutics, Inc.. 450,000 shares at an average of $22.00, traded Feb 12, 2024, filed Feb 12, 2024.
Score components
- +8RoleOther
- +25Trade size$9.9M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +10Price context0% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.5%, 3m -51.1%, 6m -78.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-014000, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 12, 2024 | CConversion Common Stockindirect: By: Northpond Ventures III, LP | +2,805,426 | - | - | 2,805,426 | Feb 12, 2024 |
| Feb 12, 2024 | POpen-market purchase Common Stockindirect: By: Northpond Ventures, LP | +450,000 | $22.00 | $9.9M | 450,000 | Feb 12, 2024 |
| Feb 12, 2024 | CConversion Series B Preferred Stockderivativeindirect: By: Northpond Ventures III, LP | -12,767,776 | - | - | 0 | Feb 12, 2024 |
Related signals
Other insiders at Kyverna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Kyverna Therapeutics, Inc. | Westlake BioPartners Opportunity Fund I, L.P. owner | $1000k 133,333 shares | +18% | |
| 51Moderate | Kyverna Therapeutics, Inc. | Beth C Seidenberg director | $1000k 133,333 shares | +18% | |
| 14Weak | Kyverna Therapeutics, Inc. | Karen Marie Walker Chief Technology Officer | $293k 23,998 shares | -51% | |
| 60Notable | Kyverna Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC owner | $9.9M 450,000 shares | +17% | |
| 65Notable | Kyverna Therapeutics, Inc. | Vida Ventures, LLC owner | $5.6M 253,136 shares | - | |
| 58Moderate | Kyverna Therapeutics, Inc. | Gilead Sciences, Inc. owner | $20M 910,000 shares | +28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.